High immunogenicity of glioma cells in vitro anti-tumor vaccine ultrastructure of target cells when.docVIP

 PAGE \* MERGEFORMAT 13 High immunogenicity of glioma cells in vitro anti-tumor vaccine ultrastructure of target cells when On: Zheng Shu law, Kang Dezhi, Lin Yuan-phase, even Paula Strong [Abstract] Objective To observe the high immunogenicity of human glioblastoma multiforme tumor (GBMU251 cell vaccine produced in vitro effect of cell killing induced ultrastructural changes of target cells. METHODS 500 U / mL interferon (IFN ) induced 48 h + 43 heat shock 2 h induced membrane-type heat shock protein 70 (HSP70) and major histocompatibility complex class I molecules (MHC I double high expression of mitomycin (MMC) made of high-inactivated cell vaccine immunogenicity. In vitro stimulation of healthy donor peripheral blood mononuclear cells (PBMCs as effector cells (MHC HSP CTL, the tumor specific anti-test, MTT assay for measuring the cytotoxic activity of target cells by transmission electron microscopy after the attack . Results MHC HSP CTL specific for wild-type U251 cells to kill tumor activity was significantly higher than the expression of HSP70 molecular single cell vaccine stimulation (HSP CTL, MHC I molecules in a single vaccine to stimulate the cells with high expression group (MHC CTL and wild-type control group (W CTL (P lt;0.05), transmission electron microscopy after an attack target cells showed different degrees of apoptosis, necrosis and oncosis-like necrosis, swelling and necrotic cell death-like cells in the high immunogenicity of the vaccine to stimulate the effector cells group more. Conclusion mediated oncosis is a high immunogenicity of the membrane-type HSP70 and MHC I molecule dual U251 cells with high expression of the vaccine’s active specific vaccine is an important anti-tumor mechanism. [Keywords:] gene, MHC class, IFN type , heat shock protein 70, glioma, cell lines, tumors, cancer vaccines, immunotherapy, microscopy, electron Heat shock protein 70 (heat shock protein 70, HSP70) and major histocompatibility complex an